# reload+after+2024-01-23 00:46:30.033390
address1§41 Ninth Avenue
address2§14th Floor
city§New York
state§NY
zip§10001
country§United States
phone§646 661 7661
fax§646 661 4027
website§https://www.ovidrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
fullTimeEmployees§39
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir', 'age': 70, 'title': 'President, CEO & Chairman', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 923545, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey A. Rona', 'age': 55, 'title': 'Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 686280, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason  Tardio M.B.A.', 'age': 46, 'title': 'Chief Operating Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 652840, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D.', 'age': 66, 'title': 'Founder & Member of Scientific Advisory Board', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 669929, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lora  Pike', 'title': 'Senior Director of Investor Relations & Public Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas Michael Perone J.D., M.B.A.', 'age': 58, 'title': 'General Counsel', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 632106, 'exercisedValue': 0, 'unexercisedValue': 67187}, {'maxAge': 1, 'name': 'Mr. Simon D. Kelner', 'age': 49, 'title': 'Chief Human Resources Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dirk  Haasner', 'age': 58, 'title': 'Senior Vice President of Global Manufacturing & CMC QA', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 416952, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Todd F. Baumgartner M.D., M.P.H.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Julia  Tsai Ph.D.', 'age': 48, 'title': 'Senior Vice President of Clinical Development', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§7
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.756
priceToSalesTrailing12Months§727.2844
currency§USD
dateShortInterest§1702598400
forwardEps§-0.66
exchange§NMS
quoteType§EQUITY
shortName§Ovid Therapeutics Inc.
longName§Ovid Therapeutics Inc.
firstTradeDateEpochUtc§1493991000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§51982f47-ea34-3602-8b3b-2a8cb7696156
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§4.0
targetMeanPrice§7.25
targetMedianPrice§7.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§10.05
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
